Skip to Content

Interferon beta-1b Disease Interactions

There are 4 disease interactions with interferon beta-1b:

Major

Interferons (Includes Interferon beta-1b) ↔ Cardiac Disease

Severe Potential Hazard, High plausibility

Applies to: Ischemic Heart Disease, Arrhythmias, Congestive Heart Failure, Cardiovascular Disease

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
View all 4 references
Major

Interferons (Includes Interferon beta-1b) ↔ Cns Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Seizures, Parkinsonism, Psychosis

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
View all 4 references
Major

Interferons (Includes Interferon beta-1b) ↔ Depression

Severe Potential Hazard, High plausibility

Applies to: Depression

Interferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.

References

  1. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  2. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
  3. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
View all 4 references
Major

Interferons-Beta (Includes Interferon beta-1b) ↔ Hepatic Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs. Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.

interferon beta-1b drug Interactions

There are 450 drug interactions with interferon beta-1b

interferon beta-1b alcohol/food Interactions

There is 1 alcohol/food interaction with interferon beta-1b

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide